ArticleJournal of nanobiotechnology2024
Smart osteoclasts targeted nanomedicine based on amorphous CaCO
Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Surface-Engineered Phytochemical Nanomedicines for Postmenopausal Osteoporosis: Skeletal Targeting, Imaging-Supported Evaluation, and Therapeutic Performance.Pharmaceutics · 2026Review
- Spatiotemporally adaptive metal-gas nanotherapy: Acid-triggered cascade release for osteoporosis treatment.Bioactive materials · 2026Article
- Application and prospects of nanomaterials in osteoporosis treatment.International journal of pharmaceutics: X · 2026Review
- Biomimetic materials for medical applications.Chinese medical journal · 2026Review
- Sea cucumber-inspired dual-responsive black phosphorus/amorphous calcium-based bone-targeting nanoplatform for synergistic therapy of osteoporosis.Journal of nanobiotechnology · 2026Article
- Advancements in bone organoids: perspectives on construction methodologies and application strategies.Journal of advanced research · 2026Review
- Schwann cell-derived extracellular vesicles inhibit osteoclastogenesis through the PTEN/AKT axis in peripheral nerve-bone crosstalk.Journal of nanobiotechnology · 2026Article
- Acid-Responsive Nanocarriers for Site-Specific Osteoclast Inhibition and Osteoporosis Therapy: A Review.International journal of nanomedicine · 2026Review
- Targeting Inflammation-Oxidative Stress Crosstalk: Advances and Challenges in Nanocarrier-Based Interventional Strategies for Pulmonary Arterial Hypertension.International journal of nanomedicine · 2026Review
- How Emerging Nanomaterials are Effective in Bone Regeneration?International journal of nanomedicine · 2026Review
- Biocompatible Mesoporous Materials for Bone Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Efficacy of 12-month romosozumab monotherapy or combination with eldecalcitol in patients with osteoporosis with and without chronic kidney disease: A real-world retrospective study.Biomedical reports · 2025Article
- Unraveling Ginsenoside Rg1's osteoprotective pathways in zebrafish models of glucocorticoid induced osteoporosis via transcriptomics.Scientific reports · 2025Article
- Biomimetic structural design in 3D-printed scaffolds for bone tissue engineering.Materials today. Bio · 2025Review
- Targeted Dual Microdroplets for Modulating Osteoclast Differentiation and Function: A Novel Therapeutic Approach to Combat Osteoporosis.ACS applied materials & interfaces · 2025Article
- DNA-encoded dynamic hydrogels for 3D bioprinted cartilage organoids.Materials today. Bio · 2025Review
- Advanced Microarrays as Heterogeneous Force-Remodeling Coordinator to Orchestrate Nuclear Configuration and Force-Sensing Mechanotransduction in Stem Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The Emerging Roles of Nano Drug Delivery Systems in Treatment of Osteoporosis-Current Knowledge, Challenges and Future Perspectives.International journal of nanomedicine · 2025Review
- Immunomodulatory Effects and Mechanisms of Two-Dimensional Black Phosphorus on Macrophage Polarization and Bone Regeneration.International journal of nanomedicine · 2025Review
- Ancient Medicinal InsectInternational journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundOsteoporosis is characterized by an imbalance in bone homeostasis, resulting in the excessive dissolution of bone minerals due to the acidified microenvironment mediated by overactive osteoclasts. Oroxylin A (ORO), a natural flavonoid, has shown potential in reversing osteoporosis by inhibiting osteoclast-mediated bone resorption. The limited water solubility and lack of targeting specificity hinder the effective accumulation of Oroxylin A within the pathological environment of osteoporosis.
resultsOsteoclasts' microenvironment-responsive nanoparticles are prepared by incorporating Oroxylin A with amorphous calcium carbonate (ACC) and coated with glutamic acid hexapeptide-modified phospholipids, aiming at reinforcing the drug delivery efficiency as well as therapeutic effect. The obtained smart nanoparticles, coined as OAPLG, could instantly neutralize acid and release Oroxylin A in the extracellular microenvironment of osteoclasts. The combination of Oroxylin A and ACC synergistically inhibits osteoclast formation and activity, leading to a significant reversal of systemic bone loss in the ovariectomized mice model.
conclusionThe work highlights an intelligent nanoplatform based on ACC for spatiotemporally controlled release of lipophilic drugs, and illustrates prominent therapeutic promise against osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.